TFA Therapeutics (RAJAF) Total Non-Current Liabilities (2020 - 2025)

TFA Therapeutics has reported Total Non-Current Liabilities for 6 years, with the latest figure at $5.0 million in Q4 2025.

• On a quarterly basis, Total Non-Current Liabilities rose 3.61% year-over-year to $5.0 million in Q4 2025; TTM through Dec 2025 was $5.0 million, a 3.61% increase from a year earlier, with the FY2025 full-year figure at $5.0 million, up 3.61% from the prior year.
• Total Non-Current Liabilities was $5.0 million for Q4 2025 at TFA Therapeutics, up from $4.8 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $5.0 million in Q4 2025, with the low at $1.7 million in Q4 2022.
• Average Total Non-Current Liabilities over 5 years is $3.4 million, with a median of $3.5 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities dropped 15.14% in 2022, then jumped 107.66% in 2023.
• Over 5 years, Total Non-Current Liabilities stood at $2.0 million in 2021, then retreated by 15.14% to $1.7 million in 2022, then jumped by 107.66% to $3.5 million in 2023, then jumped by 37.84% to $4.8 million in 2024, then increased by 3.61% to $5.0 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $5.0 million (Q4 2025), $4.8 million (Q4 2024), and $3.5 million (Q4 2023), per Business Quant data.